GeneDx Holdings Corp. WGS
0 trading plans running, 8 Form 144 notices for $21.7M
10-Q, 10-K and Form 144What WGS's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Aug 16, 2024 to Nov 16, 2026. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Bryan Dechairo Chief Operating Officer |
Adopted 10b5-1 plan | Sep 15, 2025 | 10-Q Oct 28, 2025 | ||
What the company wroteOn September 15, 2025, Bryan Dechairo, our Chief Operating Officer, entered into a written plan for the potential sale of up to an aggregate of 9,374 shares of our Class A common stock, including shares underlying Mr. Dechairo’s RSU awards (the “Dechairo 10b5-1 Plan” and, together with the Stueland 10b5-1 Plan, the “10b5-1 Plans”). The Dechairo 10b5-1 Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and will be effective from February 4, 2026 to September 30, 2026. | |||||
| Katherine Stueland Chief Executive Officer |
Adopted 10b5-1 plan | Sep 11, 2025 | 10-Q Oct 28, 2025 | ||
What the company wroteOn September 11, 2025, Katherine Stueland, our Chief Executive Officer, entered into a written plan for the potential sale of up to an aggregate of 40,000 shares of our Class A common stock, including shares underlying Ms. Stueland’s restricted stock unit (“RSU”) awards (the “Stueland 10b5-1 Plan”). The Stueland 10b5-1 Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and will be effective from April 10, 2026 to October 30, 2026. | |||||
| Jason Ryan chairman and a director |
Ended 10b5-1 plan | Aug 27, 2025 | 10-Q Oct 28, 2025 | ||
What the company wroteOn August 27, 2025, a grantor annuity trust (the “GRAT”) of which Jason Ryan, our chairman and a director, is the trustee, terminated a written plan for the potential transfer of up to an aggregate of 141,356 shares of our Class A common stock that had previously been entered into on November 7, 2024 (the “Ryan GRAT 10b5-1 Plan”). The Ryan GRAT 10b5-1 Plan was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and had provided that it would be effective until March 5, 2027. | |||||
| Jason Ryan chairman and a director |
Adopted 10b5-1 plan | Nov 7, 2024 | 10-K Feb 20, 2025 | ||
What the company wroteOn November 7, 2024, a grantor annuity trust (the “GRAT”) of which Jason Ryan, our chairman and a director, is the trustee, entered into a written plan for the potential transfer of up to an aggregate of 141,356 shares of our Class A common stock (the “Ryan GRAT 10b5-1 Plan”). The Ryan GRAT 10b5-1 Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and will be effective from November 19, 2025 to March 5, 2027. | |||||
| Kevin Feeley Chief Financial Officer |
Adopted 10b5-1 plan | Aug 21, 2024 | 10-Q Oct 29, 2024 | ||
What the company wroteOn August 21, 2024, Kevin Feeley, our Chief Financial Officer, entered into a written plan for the potential sale of up to an aggregate of 117,713 shares of our Class A common stock, including shares underlying Mr. Feeley’s RSU and stock option awards (the “Feeley 10b5-1 Plan”). The Feeley 10b5-1 Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and will be effective from November 21, 2024 to October 30, 2025. | |||||
| Katherine Stueland Chief Executive Officer |
Adopted 10b5-1 plan | Aug 16, 2024 | 10-Q Oct 29, 2024 | ||
What the company wroteOn August 16, 2024, Katherine Stueland, our Chief Executive Officer, entered into a written plan for the potential sale of up to an aggregate of 312,808 shares of our Class A common stock, including shares underlying Ms. Stueland’s restricted stock unit (“RSU”) awards (the “Stueland 10b5-1 Plan”). The Stueland 10b5-1 Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and will be effective from November 15, 2024 to October 30, 2025. | |||||
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Sep 1, 2026 | Kevin Feeley Officer |
5,410 | $458K |
| Sep 1, 2026 | Katherine Stueland Officer, Director |
14,243 | $1.2M |
| Apr 29, 2026 | Kevin Feeley Officer |
5,804 | $366K |
| Apr 29, 2026 | Katherine Stueland Director, Officer |
16,415 | $1.0M |
| Feb 2, 2026 | Bryan Dechairo Officer |
9,374 | $930K |
| Jan 29, 2026 | Kevin Feeley Officer |
24,155 | $2.4M |
| Jan 29, 2026 | Katherine Stueland Officer, Director |
94,495 | $9.3M |
| Nov 24, 2025 | RUCH JOSHUA Director |
38,000 | $6.1M |
From the Form 144 XML filed with the SEC, since Nov 24, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/WGS/export.csv") into a cell.